Viewing nowCombinationSitagliptin/Metformin Extended Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.

MFDS item code 202202040 · Approved 2022.05.16 · Insurance code 649606200
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood sugar management for patients with type 2 diabetes along with diet and exercise regimens. The combination of sitagliptin and metformin effectively lowers blood sugar levels, thereby helping to improve blood sugar management in patients.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients being treated with metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg. The initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains the active ingredients sitagliptin and metformin. Firstly, the sitagliptin component may cause allergic reactions, so if symptoms such as rash, hives, or difficulty breathing occur, discontinue use immediately and consult a physician. Additionally, sitagliptin can cause pancreatitis, which is inflammation of the pancreas, so if abdominal pain, vomiting, or nausea occurs, notify medical personnel immediately. Although rare, the metformin component can cause serious metabolic abnormalities known as lactic acidosis, so if symptoms such as difficulty breathing, muscle pain, fatigue, or abdominal pain appear, discontinue the medication immediately and seek hospitalization. This drug should not be administered to patients with moderate to severe renal impairment, acute diseases such as acute heart failure or severe infections, patients with liver dysfunction, or women who are pregnant or breastfeeding. Patients scheduled for surgery should stop taking this medication 48 hours prior to the procedure and may resume after confirming normal renal function post-surgery. Patients with irregular eating habits or poor nutritional status, those who engage in vigorous exercise, or those taking other medications are at higher risk for hypoglycemia or lactic acidosis and should use caution. During treatment, regular monitoring of blood glucose, renal function, and vitamin B12 levels should be performed to check for abnormalities. Alcohol can increase the risk of side effects from this medication, so patients should avoid drinking while taking it. If hypoglycemic symptoms occur, consume sugar immediately and seek medical advice if symptoms are severe. If skin blisters or severe joint pain occur while taking this medication, consult a physician immediately. Lastly, when administering this medication to the elderly, renal function should be closely monitored and dosage adjustments may be necessary.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture. The appropriate storage temperature is between 1 and 30 degrees Celsius at room temperature, and it is important not to expose it to extreme heat or cold.
Bright green oval-shaped extended release film-coated tablets, biconvex on both sides.
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.